Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Maurizio Zangari

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Zangari, Maurizio

PropertyValue
research overview Hypercoagulability in Cancer Patients. The role of activated protein C in thrombotic manifestation of patients with multiple myeloma. Since the start at the University of Utah I have initiated retrospective and prospective studies of the protein C system function in patients with paraproteinemias and myeloproliferative disorder. I have also continued to test the effect of proteosome inhibition on platelet function. After establishing 5GTM1 C57BL/KaLwRij sub-strain in a pre-clinical model I have tested the function of a proteasome inhibitor through the PTH-PTHR axis. In the last 22 months I focused the research to confirm the hypothesis of the PTH essential role in anti-myeloma proteasome activity testing the effect of PTHR antibodies and the effects of parathyroidectomy. The C57 BLACK MOUSE MODEL will be measured in the presence of different proteasome inhibitors MLN 9708, carfilzomib and CEP 18770. I am the principal investigator in three open investigator-initiated trials (Phase I Exploratory Study of Panobinostat IV in Combination with Relapsed/Refractory Multiple Myeloma Patients; Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients; Bone Effect of Bortezomib in Patients with relapsed/refractory Multiple Myeloma), which focus on the bone anabolic activity of proteasome inhibition to determine the minimal proteosome inhibition associated with the anabolic bone effect in multiple myeloma and to evaluate the effect of proteasome inhibition in smoldering myeloma patients. A phase I study, a combination of two bone anabolic drugs panabinostat (a histone deacetylase inhibitor HDAC) and bortezomib in relapse/refractory multiple myeloma patients.

One or more keywords matched the following items that are connected to Zangari, Maurizio

Item TypeName
Concept Antibodies
Concept Antibodies, Monoclonal
Concept Antibodies, Bispecific
Concept Antibodies, Monoclonal, Humanized
Academic Article A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.
Academic Article Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Academic Article Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Academic Article Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Academic Article Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Academic Article Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Academic Article Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Academic Article The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Academic Article Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Academic Article Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Search Criteria
  • Antibodies